- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07811219
RESP-FIT: A Respiratory Muscle Strength Training Intervention for COPD
10 de septiembre de 2026 actualizado por: Medical University of South Carolina
Individuals with chronic obstructive pulmonary disease (COPD) often experience dyspnea, low physical activity, and reduced quality of life.
RESP-FIT is a randomized controlled trial evaluating a remotely delivered respiratory muscle strength training intervention combined with mobile health tools to improve dyspnea, respiratory muscle strength, and physical activity in adults with COPD.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Intervención / Tratamiento
Descripción detallada
This randomized, parallel-group clinical trial will enroll adults with COPD and assign them 1:1 to either the RESP-FIT intervention or enhanced usual care.
The RESP-FIT intervention includes respiratory muscle strength training using a commercially available inspiratory muscle trainer, remote spirometry, physical activity monitoring, ecological momentary assessment of symptoms, and a mobile application for monitoring and feedback.
Primary and secondary outcomes include dyspnea, dyspnea-related kinesiophobia, respiratory muscle strength, physical activity, lung function, and quality of life, assessed over a 6-month follow-up period.
All study activities are conducted remotely.
Tipo de estudio
Intervencionista
Inscripción (Estimado)
288
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Mary Chris S. Pittman, BA
- Número de teléfono: 8437923512
- Correo electrónico: pittmama@musc.edu
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Descripción
Inclusion Criteria:
- Age ≥40 years
- Clinical diagnosis of COPD
- Ability to provide informed consent
- Willingness to use mobile health devices and apps
- Access to Wi-Fi and mailing address in the U.S.
Exclusion Criteria:
- Cognitive impairment preventing participation
- Active substance abuse
- Other significant respiratory disease
- Concurrent enrollment in conflicting COPD or behavioral intervention trials
- Non-English speaking
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: RESPFIT Intervention Arm
The RESP-FIT intervention group will receive the full intervention, including respiratory muscle strength training (RMST), ecological momentary assessment (EMA) symptom tracking through the mobile application, and physical activity monitoring using an activity monitor.
Participants will receive instructions from study personnel on RMST device use and will follow a simple 5x5x5 training protocol (5 breaths, 5 times a day, 5 times a week) over the intervention period.
Participants will be asked to record training sessions and symptoms using the mobile application.
The intervention period will last 6 months, with the primary endpoint occurring at 3 months following baseline.
Outcome assessments will occur at baseline and at 1, 2, 3, and 6 months.
|
The RESP-FIT intervention group will receive the full intervention, including respiratory muscle strength training (RMST), EMA symptom management through the RESP-FIT app, ecological momentary assessment (EMA) symptom tracking through the mobile application, and physical activity monitoring using the Garmin activity monitor.
Participants will receive instructions from study personnel on RMST device use and will follow a simple 5x5x5 training protocol (5 breaths, 5 times a day, 5 times a week) over the intervention period of 6 months.
Participants will also be asked to record training sessions and symptoms using the mobile application.
Participants will receive on-going support and monitoring from study personnel for the first 3 months and can use app and devices at will for the next 3 months until the 6 month assessment period when the study procedures end.
|
|
Sin intervención: No Intervention Enhanced Usual Care Group
Participants randomized to the control group will receive enhanced usual care (eUC).
This consists of their standard COPD management provided by their healthcare providers along with the mobile app for remote spirometry and symptom tracking and physical activity monitoring using the Garmin wearable activity tracker.
Control group participants will also receive publicly available COPD educational materials (via COPD Foundation resources).
Providing an activity monitor to both groups allows the research team to account for potential effects of activity monitoring on physical activity behavior.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Maximal Inspiratory Pressure (PImax)
Periodo de tiempo: Baseline to 3 Months
|
Maximal inspiratory pressure measured using the POWERbreathe Smart Adaptor digital pressure transducer connected to a mouthpiece.
|
Baseline to 3 Months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Modified Borg Dyspnea Scale Score
Periodo de tiempo: Baseline to 3 Months
|
Dyspnea severity assessed using the Modified Borg Scale delivered through ecological momentary assessment (EMA) within the study mobile application.
Scores range from 0-10, with 0 indicating no breathlessness and 10 indicating maximal breathlessness.
Higher scores indicate greater dyspnea severity.
|
Baseline to 3 Months
|
|
Change in Breathlessness Beliefs Questionnaire (BBQ) Score
Periodo de tiempo: Baseline to 3 Months
|
Dyspnea-related kinesiophobia assessed using the Breathlessness Beliefs Questionnaire (BBQ), a validated 11-item instrument that measures dysfunctional beliefs about breathlessness related to physical activity.
Items are rated on a 5-point scale, yielding a total score ranging from 11-55, with higher scores indicating stronger beliefs about breathlessness and greater dyspnea-related fear and activity avoidance.
|
Baseline to 3 Months
|
|
Change in Modified Medical Research Council (mMRC) Dyspnea Scale Score
Periodo de tiempo: Baseline to 3 Months
|
Breathlessness measured using the Modified Medical Research Council (mMRC) Dyspnea Scale, a 5-grade scale that assesses the degree to which breathlessness limits daily physical activities.
Scores range from 0-4, with higher scores indicating breathlessness that prevents leaving the house or occurring during dressing/undressing.
Higher scores indicate worse dyspnea-related functional limitation.
|
Baseline to 3 Months
|
|
Change in PROMIS Dyspnea-Related Activity Avoidance Score
Periodo de tiempo: Baseline to 3 Months
|
Activity avoidance due to breathing discomfort assessed using the PROMIS Dyspnea-Related Activity Avoidance instrument.
This is a 5 point Likert scale with 3 items measuring avoidance of activities due to shortness of breath or phsyical limitations over the past 7 days, scored from 0 (not at all) to 4 (very much), yielding total raw score range of 0-12.
Higher scores indicate greater dyspnea-related task avoidance.
|
Baseline to 3 Months
|
|
Change in St. George's Respiratory Questionnaire (SGRQ) Total Score
Periodo de tiempo: Baseline to 3 Months
|
Respiratory-related quality of life assessed using the St. George's Respiratory Questionnaire (SGRQ) for COPD.
This is contains 40 items assessing three domains (symptoms, activity, and impact) and a total score ranging from 0-100, with 0 indicating no impairment and 100 indicating maximum impairment.
Higher scores indicate greater impairment in respiratory related quality of life.
|
Baseline to 3 Months
|
|
Change in Average Daily Step Count
Periodo de tiempo: Baseline to 3 Months
|
Physical activity measured using a Garmin wearable activity monitor, with daily steps captured numerically in number of steps.
|
Baseline to 3 Months
|
|
Change in CAPTURE Score
Periodo de tiempo: Baseline to 3 Months
|
COPD symptoms and exacerbation risk assessed using the COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) questionnaire.
This is a 5 item instrument assessing respiratory symptoms, risk exposures, recent acute respiratory illnesses with a total score range of 0-6, with higher scores indicating greater likelihood of clinically significant COPD and exacerbation risk.
|
Baseline to 3 Months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Qualitative Measures
Periodo de tiempo: 3 months
|
Semi-structured interviews assessing intervention accessibility, usability, symptom monitoring, dyspnea-related activity avoidance, disease self-management, and overall participant experiences with RESP-FIT
|
3 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Sarah Miller, PhD, RN, Medical University of South Carolina
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
15 de septiembre de 2026
Finalización primaria (Estimado)
15 de abril de 2030
Finalización del estudio (Estimado)
15 de mayo de 2031
Fechas de registro del estudio
Enviado por primera vez
21 de agosto de 2026
Primero enviado que cumplió con los criterios de control de calidad
4 de septiembre de 2026
Publicado por primera vez (Actual)
10 de septiembre de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
15 de septiembre de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
10 de septiembre de 2026
Última verificación
1 de septiembre de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Trastornos de la respiración
- Enfermedades Pulmonares Obstructivas
- Signos y Síntomas Respiratorios
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Enfermedad Pulmonar Obstructiva Crónica
- Disnea
Otros números de identificación del estudio
- Pro00149990
- 1R01NR021347-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
SÍ
Descripción del plan IPD
Study Protocol
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
producto fabricado y exportado desde los EE. UU.
Sí
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .